754 related articles for article (PubMed ID: 19671853)
1. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
2. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I; Steinle A
Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
[TBL] [Abstract][Full Text] [Related]
3. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
Egberts F; Pollex A; Egberts JH; Kaehler KC; Weichenthal M; Hauschild A
Onkologie; 2008 Jul; 31(7):380-4. PubMed ID: 18596385
[TBL] [Abstract][Full Text] [Related]
5. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.
Rebmann V; Schütt P; Brandhorst D; Opalka B; Moritz T; Nowrousian MR; Grosse-Wilde H
Clin Immunol; 2007 Apr; 123(1):114-20. PubMed ID: 17218152
[TBL] [Abstract][Full Text] [Related]
6. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
Wittenbrink M; Spreu J; Steinle A
Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
[TBL] [Abstract][Full Text] [Related]
7. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia.
Nückel H; Switala M; Sellmann L; Horn PA; Dürig J; Dührsen U; Küppers R; Grosse-Wilde H; Rebmann V
Leukemia; 2010 Jun; 24(6):1152-9. PubMed ID: 20428196
[TBL] [Abstract][Full Text] [Related]
9. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
[TBL] [Abstract][Full Text] [Related]
10. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
12. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma.
Helfrich I; Edler L; Sucker A; Thomas M; Christian S; Schadendorf D; Augustin HG
Clin Cancer Res; 2009 Feb; 15(4):1384-92. PubMed ID: 19228739
[TBL] [Abstract][Full Text] [Related]
13. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
Harpio R; Einarsson R
Clin Biochem; 2004 Jul; 37(7):512-8. PubMed ID: 15234232
[TBL] [Abstract][Full Text] [Related]
14. Expression of stress ligands of the immunoreceptor NKG2D in melanoma: regulation and clinical significance.
Paschen A; Baingo J; Schadendorf D
Eur J Cell Biol; 2014; 93(1-2):49-54. PubMed ID: 24629838
[TBL] [Abstract][Full Text] [Related]
15. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.
Egberts F; Momkvist A; Egberts JH; Kaehler KC; Hauschild A
Anticancer Res; 2010 May; 30(5):1799-805. PubMed ID: 20592382
[TBL] [Abstract][Full Text] [Related]
16. [Role of S100B protein in neoplasms and other diseases].
Bánfalvi T; Gergye M; Beczássy E; Gilde K; Ottó S
Magy Onkol; 2004; 48(1):71-4. PubMed ID: 15105899
[TBL] [Abstract][Full Text] [Related]
17. The predictive value of soluble major histocompatibility complex class I chain-related molecule A (MICA) levels on heart allograft rejection.
Suárez-Alvarez B; López-Vázquez A; Díaz-Molina B; Bernardo-Rodríguez MJ; Alvarez-López R; Pascual D; Astudillo A; Martínez-Borra J; Lambert JL; González S; López-Larrea C
Transplantation; 2006 Aug; 82(3):354-61. PubMed ID: 16906033
[TBL] [Abstract][Full Text] [Related]
18. Serum markers in skin melanoma--preliminary study.
Dumitraşcu G; Constantin C; Manda G; Hristescu S; Mărgaritescu I; Chiriţă D; Neagu M
Roum Arch Microbiol Immunol; 2009; 68(3):125-35. PubMed ID: 20361532
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients.
Faries MB; Gupta RK; Ye X; Lee C; Yee R; Leopoldo Z; Essner R; Foshag LJ; Elashoff D; Morton DL
Cancer Invest; 2007 Aug; 25(5):285-93. PubMed ID: 17661202
[TBL] [Abstract][Full Text] [Related]
20. Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism.
Holdenrieder S; Eichhorn P; Beuers U; Samtleben W; Stieber P; Nagel D; Peterfi A; Steinle A; Salih HR
Anticancer Res; 2007; 27(4A):2041-5. PubMed ID: 17649819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
